Literature DB >> 11994018

Pros and cons for the development of new antiepileptic drugs.

Meir Bialer1, Matthew C Walker, Josemir W Sander.   

Abstract

There continues to be an escalation in the number of new antiepileptic drugs, with many recently marketed drugs and many more entering clinical trials. This growth begs the question as to whether we need additional antiepileptic drugs. We consider the answer to this question from the medical perspective and also from the viewpoint of the pharmaceutical industry, health providers and from a more global, international perspective. There is undoubtedly a medical need for new antiepileptic drugs, and despite growing competition, the antiepileptic drug market remains profitable. However, in health services with limited resources, it is important that this expense is not offset by failure to research more appropriate use of existing antiepileptic drugs that may have a greater impact on healthcare. This is especially true for developing countries where resources would be much better spent on prevention and closing the treatment gap (the difference between those who can be treated and those who are treated).

Mesh:

Substances:

Year:  2002        PMID: 11994018     DOI: 10.2165/00023210-200216050-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  24 in total

1.  Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs.

Authors:  M C Walker; J W Sander
Journal:  Neurology       Date:  1997-08       Impact factor: 9.910

2.  Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy?

Authors:  P M Foy; D W Chadwick; N Rajgopalan; A L Johnson; M D Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

Review 3.  Do new antiepileptic drugs justify their expense?

Authors:  D Chadwick
Journal:  Arch Neurol       Date:  1998-08

Review 4.  Epidemiology of the epilepsies.

Authors:  J W Sander; S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

Review 5.  Neurocysticercosis and epilepsy in developing countries.

Authors:  D K Pal; A Carpio; J W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

6.  Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. ICBERG (International Community-based Epilepsy Research Group)

Authors:  A T Feksi; J Kaamugisha; J W Sander; S Gatiti; S D Shorvon
Journal:  Lancet       Date:  1991-02-16       Impact factor: 79.321

7.  Prophylactic antiepileptic agents after head injury: a systematic review.

Authors:  G Schierhout; I Roberts
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

Review 8.  Epilepsy in developing countries: a review of epidemiological, sociocultural, and treatment aspects.

Authors:  S D Shorvon; P J Farmer
Journal:  Epilepsia       Date:  1988       Impact factor: 5.864

9.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.

Authors:  R H Mattson; J A Cramer; J F Collins; D B Smith; A V Delgado-Escueta; T R Browne; P D Williamson; D M Treiman; J O McNamara; C B McCutchen
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

Review 10.  Some aspects of prognosis in the epilepsies: a review.

Authors:  J W Sander
Journal:  Epilepsia       Date:  1993 Nov-Dec       Impact factor: 5.864

View more
  1 in total

Review 1.  Valproic Acid: second generation.

Authors:  Meir Bialer; Boris Yagen
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.